Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Wards Off More Januvia Infringers In India

This article was originally published in Scrip

Executive Summary

Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), or hope to introduce copies of these on the domestic market, infringing on its patents.

You may also be interested in...



Januvia Generics Arrive In India

A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the originator respond with price cuts?

Januvia Generics Arrive: Can MSD Defend Its Turf In India?

A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the company respond with price cuts?

Merck-Teva Legal Wrangle Over Januvia "R&D" In India

Merck & Co continues to keep a hawk eye on alleged infringement activities in India pertaining to its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride). It has hauled Teva to court for allegedly manufacturing and selling sitagliptin, though the Israeli multinational has claimed that its efforts were geared only towards regulatory submissions.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC030227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel